TOKYO -- SoftBank Group will launch a Japan-focused medical service using artificial intelligence to analyze personal medical data, including genes, through a joint venture with U.S. health care company Tempus AI, Nikkei has learned.
The venture will be capitalized at 30 billion yen ($188 million), with SoftBank Group and Tempus AI both owning a 50% share. It will begin work as early as July, and aims to start providing services within one to two years.
